Posts

new lipoprotein(a) inhibitor pelacarsen was withdrawn after trial

as a reference to the Lp(a) studies in the pipeline, one of which involved direct PCSK9 effects: enclisiran (which is also spelled inclisiran in the NJM study...), which the FDA unexpectedly (by me) approved without documentation of clinical benefit: https://gmodestmedblogs.blogspot.com/2025/11/oral-pcsk9-improves-all-bad-lipids.html  - -- as a summary of what I have found of several of these Lp(a) inhibitors:     -- muvalapin (oral small-molecule): 63-65% reduction in Lp(a), with benefit within 4 weeks: https://jamanetwork.com/journals/jama/fullarticle/2808864       -- pelacarsen (antisense oligonucleotide that targets the Lp(a) gene): up to 80% reduction in Lp(a):   https://www.sciencedirect.com/science/article/pii/S1933287425003228     -- evinacumab (anti-ANGPTL3 mAb): 16.5% reduction in Lp(a): https://www.sciencedirect.com/science/article/pii/S1933287425003228     -- lomitapide (microsomal triglyceride transf...
Post a Comment
Read more

are GLP1's associated with pancreatitis??

Image
  A recent study found that GLP-1 receptor agonists were not associated with more acute pancreatitis than sulfonylureas. There was a small increase in GLP-1 related pancreatitis that was offset by decreased alcohol- and triglyceride-related pancreatitis attributable to the GLP-1s: see GLP-1 pancreatitisBMJ2026 in dropbox, or doi:10.1136/ bmjmed-2025-002183 Details : -- 333,687 patients were studied who had type 2 diabetes and antidiabetic therapy was initiated by a GLP-1 receptor agonist (n=132,551) or a sulfonylurea (n= 201,136), between January 2017 and January 2024, from the Veterans Affairs healthcare system databases -- mean age 66, 75% white/21% black -- smoking: never 43%/former 38%/current 20%; alcohol use disorder 6% -- area deprivation index 57 (a composite of socioeconomic disadvantage based on education, income, employment, and other poverty measures, measured at the participants' location, with values ranging from low to high of 0 to 100) -- BMI 34, A1c 8.6%, eGFR 76 -...
Post a Comment
Read more

is the new PCSK9 pill ready for prime time??

Image
  this past July, The FDA approved enclicitide, a new oral proprotein convertase subtilisin–kexin type 9 ( PCSK9) inhibitor that goes by trade name Lipfendra , based on the CORALreef Lipids study ; it has a price of $315 for a 30-day supply by Merck: see lipid PCSK9 oral NEJM2026 in dropbox or DOI: 10.1056/NEJMoa2511002 Details: -- the CORALreef Lipids study was a multinational, double-blind, randomized, placebo-controlled drug company-sponsored trial that enrolled 2909 adult participants in the intention-to-treat population, where 1935 received enlicitide and 969 received placebo -- this study involved 168 sites in 14 countries (including the US, UK, Italy, South Africa, Colombia, Japan, Argentina, Spain, and China) -- the participants had a history of a major atherosclerotic cardiovascular disease event (which included acute coronary syndrome, coronary revascularization, MI, ischemic stroke, cerebrovascular arterial revascularization, and peripheral arterial disease with a histo...
Post a Comment
Read more